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Microvascular Changes in Renal Allografts 
Associated with FK506 (Tacrolimus) Therapy 
P.S. Randhawa, M.D., A.C. Tsamandas . Ma none, 
M. Jordan, M.D., R. Shapiro, M.D. T.E. Starzl, M.D., Ph.D., and 
A.J. Demetris, M.D. 
FK506 (Tacrolimusl recently has been shown to be an 
effective immunosuppressant after renal transplantation. 
It is associated with less hypertension, hypercholesterol-
emia and steroid use compared with cyclosporine. We 
report 10 patients on FK506 who showed fibrin thrombi 
within the glomerular capillaries and/or arterioles at renal 
allograft biopsy. These biopsies were generally per-
formed to assess increasing serum creatinine levels; lab-
oratory evidence of hemolytic uremic syndrome was 
present in one instance. Plasma or whole blood FK506 
levels were elevated in eight of \0 cases. Reduction of 
immunosuppression led to clinical improvement or bi-
opsy-proven resolution of thrombi in all cases. These ob-
servations suggest that FK506 may occasionally produce 
microvascular changes in the renal allograft. The esti-
mated incidence of this occurrence (I %) is comparable 
with that reported with cyclosporine (3%). 
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FK506 (Tacrolimus, Fujisawa USA. Inc.) is a 
new immunosuppressive agent that recently has 
been approved by the U.S. Food and Drug Admin-
istration for use in liver transplant recipients (3,26). 
The results in kidney transplantation also have been 
encouraging. Patient and graft survival rates are as 
good as or better than those possible with cyclo-
sporine (CS), often at lower maintenance doses of 
steroids, with lower cholesterol levels and a re-
duced incidence of hypertension (21). Nephrotoxic-
ity, comparable in degree to that seen with CS, is a 
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significant side effect of FK506 but is readily man-
aged by adjustments in drug dosage (7.8,21). We 
and others have shown that renal allograft biopsies 
performed during acute episodes of FK506 toxicity 
most commonly show tubular or myocyte vacuol-
ization (4,7,19). In patients maintained long-term on 
FK506, arteriolar hyalinosis and interstitial fibrosis 
similar to that reported with CS is described (19). 
There are isolated case reports suggesting that 
FK506 also can injure the renal allograft microvas-
culature (6,8,19,20). However, detailed clinical in-
formation was not provided in these studies, mak-
ing a reasonable evaluation of this possibility diffi-
cult. The present work focuses on 10 patients in 
whom histopathological changes within the mi-
crovasculature correlated with high blood FK506 
levels and elevated serum creatinine. Reduction in 
the dosage of FK506 led to clinical or histologic 
improvement in allograft function. 
MATERIALS AND METHODS 
Patients were retrieved from a coded database of 
renal transplant recipients maintained by The Pitts-
burgh Transplant Institute over a 4-year period 
from July 1990 through June 1994. Accrual of cases 
into the study was based on the presence of fibrin 
thrombi within glomerular capillaries or afferentl 
interlobular arterioles with one to three layers of 
smooth muscle in the media. Cases with tubuli tis 
and/or active inflammation of the arterial intima 
were excluded to rule out immunologic microvas-
cular injury. Biopsies samples from kidneys known 
to have thrombosis of medium to large sized ves-
sels, or presence of discrete infarcts also were ex-
cluded because the microvascular pathology in such 
cases can be explained by ischemia alone. 
All patients were maintained on FK506 and pred-
1 
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nisone as previously described (21). Pertinent clin-
ical information was obtained by discussion with 
the attending physicians and review of the medical 
records. Particular attention was directed to serial 
changes in the FK506 dose, blood levels, and serum 
creatinine levels. Plasma FK506 levels of 0.5-2.0 
ng/ml, whole blood FK506 levels of 10.0-15.0 ng! 
ml, and serum creatinine levels of 0.2-1.1 mg/dl 
were considered to be within normal range. Histo-
pathological examination of 2-l-Lm sections of bi-
opsy tissue was performed after routine formalin 
fixation and paraffin embedding. Identification of 
fibrin thrombi was based on evaluation of slides 
stained with hematoxylin-eosin or Masson's silver 
trichrome. Tissue was not available for immunoflu-
orescence or electron microscopy. 
RESULTS 
The clinical characteristics of these cases are 
summarized in Table 1. The recipient age ranged 
from 21 to 76 years (median 49), with a male:female 
ratio of 4:6. Donor-specific cross-match performed 
by standard and antihuman globulin microcytotox-
icity assays gave negative results. Panel-reactive 
antibody testing by the Amos modified cytototox-
icity assay showed < 10% reactivity in eight cases 
and <40% reactivity in all cases. The mean donor 
organ cold ischemia time was 32.1 h (range 18.2-
56.2). The native renal disease varied, but no cases 
of hemolytic uremic syndrome or thrombotic 
thrombocytopenic purpura were included. Biopsies 
were performed for clinically significant episodes of 
allograft dysfunction. At the time of biopsy, the 
FK506 dosage was 10-45 mg/day, the plasma 
FK506 level 1.1-5.4 ng/ml (median 2.5), and the se-
rum creatinine level 1.7-8.0 mg/dl (median 3.6). In 
case 10, the whole blood FK506 level was moni-
tored and measured to be 34.8 ng/m!. The FK506 
levels were in the toxic range in eight of to cases, 
whereas the serum creatinine level was elevated in 
all patients. Cases 1 and 6 have been mentioned in 
earlier work (19,20). 
A pretransplant donor biopsy was felt to be clin-
TABLE 1. Clinical characteristics of patients with microvascular toxicity 
Age (yr) 
1 29 
2 54 
3 75 
4 47 
5 51 
6 36 
7 76 
8 21 
9 33 
10 60 
Pretreatment parameters 
FK506" Serum creatinine 
(ng/ml) (mg/dl) 
5.4 3.0 
2.7 2.5 
2.3 6.1 
2.2 3.1 
3.3 2.2 
2.1 8.0 
4.4 4.6 
1.1 4.0 
1.1 1.7 
34.8" 4.3 
Sex 
F 
M 
M 
F 
F 
F 
M 
M 
F 
F 
FKS06 
(mg/day) 
16 
36 
14 
8 
32 
a 
14 
10 
8 
5 
Pretreatment 
parameters 
FK506 
Native kidney disease Clinical onset" (mglday) 
Undetermined 24 20 
IgA nephritis 44 45 
Polycystic kidney 25 18 
Diabetes 37 10 
Diabetes 107 36 
Systemic lupus 270 14 
Glomerulonephritis 20 20 
Renal tubular acidosis 545 12 
Glomerulonephritis 240 10 
Diabetes 78 12 
Posttreatment parameters 
FK506" Serum creatinine 
(ng/ml) (mgldl) Clinical follow·up (days) 
3.6 2.0 Mild acute rejection (45) 
1.9 2.0 Borderline acute rejection (120) 
13 4.2 No follow-up biopsy 
Creatinine 1.9 mg/dl (50) 
1.2 2.7 Moderate acute rejection (84) 
1.5 1.7 Arteriolar hyalinosis (910) 
NA 4.5 No follow-up biopsy 
Creatinine 2.0 mg/dl (1,650) 
1.0 4.9 Perinephric abscess 
Allograft nephrectomy (86) 
0.7 1.7 No follow-up biopsy 
Creatinine 2.1 mg/dl (590) 
1.4 2.1 Arteriolar hyalinosis (300) 
6.6" 3.2 Creatinine 3.2 mg/dl (84) 
• Onset of clinical symptoms is recorded in days since transplantation. 
/) FK506 levels were generally measured in the plasma (normal range 0.5-2.0 ng/ml). except in case 10 in which whole blood values were 
estimated (normal 10.0-15.0 ngiml.). 
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ically indicated only in case 7, which involved a 
65-year-old donor. This specimen showed mild ar-
teriosclerosis and interstitial fibrosis. Posttrans-
plant allograft biopsies showed fibrin thrombi in the 
glomerular capillaries in eight of 10 cases and within 
arterioles in six of 10 cases (Figs. 1-3). The percent-
age of glomeruli/arterioles involved varied from 5% 
to 40% in different specimens. The arteriolar walls 
showed deposition of fibrin within the intima and/or 
media in four of 10 cases (Fig. 4). One case showed 
globules of an eosinophilic material lying in the me-
dial coat (Fig. 5). Myocyte vacuolization in the ar-
teriolar media was universally present, and endo-
thelial hypertropy was seen in four of 10 cases. A 
single case showed rare subendothelial lympho-
cytes, nuclear fragmentation, and focal coagulative 
necrosis of the media (Fig. 6). Clinical response to 
reduction in dosage of FK506 excluded rejection 
and led to its inclusion in the study. The tubular 
epithelium showed cytoplasmic vacuolization in 
eight of 10 cases; generally, fine isometric and 
coarse irregular vacuoles were present concurrently 
within the same biopsy sample. The tubular 
changes were mild and focal in four of eight cases. 
FIG. 1. A partially occlusive fibrin thrombus seen 
within the afferent arteriole of a glomerulus. The cap-
illary loops distal to the thrombus appear to be dilated. 
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FIG. 2. An isolated glomerular capillary loop throm-
bus (arrow) visualized by the Masson's silver tri-
chrome technique. 
Arteriolar hyaline change was seen in two cases at 
the time of initial biopsy (case 3 and 4) and in two 
other cases on subsequent follow-up (cases 5 and 
9). The juxtaglomerular cells showed no increase in 
number or cytoplasmic granularity, as assessed by 
routine silver staining. 
In the absence of rejection, the histopathological 
changes observed were clinically assumed to repre-
sent drug toxicity, and the dose of FKS06 was re-
duced. The median reduction in dose was 20% of 
baseline, but in case 6, in which the patient pre-
sented with frank hemolytic uremic syndrome, 
FKS06 was discontinued completely (100% reduc-
tion). These dose adjustments led to a 0.3- to 3.4-
ng/ml (median 1.0) decrease in the plasma FKS06 
level. In eight of 10 cases, a decrease in serum cre-
atinine varying from O.S to 3.S mg/dl (median 1.1) 
was observed over a period of 4-21 days (median 
6.0). Episodes of acute rejection were documented 
in cases L 2, and 4 by biopsies performed respec-
tively 45, 120, and 84 days after diagnosis of micro-
vascular injury. There was no evidence of persis-
tent capillary thrombi or mural fibrinoid change in 
these repeat specimens. Cases 5 and 9 showed ar-
• 
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FIG. 3. A diffuse deposition of fibrin involving n~arly 
all capillary loops was seen in this glomerulus. 
teriolar hyaline change in follow-up biopsies ob-
tained 300 and 910 days after initial documentation 
of drug toxicity. Patient 7 had a complicated course 
with persistent nonfunction of the graft, urinary 
leak, and perinephric abscess formation. Allograft 
nephrectomy performed on day 86 showed mild to 
moderate acute cellular rejection and persistent glo-
merular capillary thrombi. Follow-up biopsies were 
not available in cases 3, 6, 8, and 10, but stable 
serum creatinine was documented respectively 50-
1,650 days posttransplantation. 
DISCUSSION 
The potential of FK506 to cause injury to blood 
vessels was the subject of several investigations 
during the developmental phases of this drug. Vas-
cular necrosis described as vasculitis involving me-
dium-sized arteries in the liver, pancreas, and heart 
was reported in FK506-treated dogs at the Univer-
sity of Cambridge (23). Work performed at two 
other laboratories raised doubts about the signifi-
cance of these findings because vasculitis was 
found with equal frequency in control animals 
(17,24). Investigators in other studies were unable 
to reproduce vasculitis lesions in rats, baboons, or 
monkeys treated with FK506 (16,25). Arteriolar-
sized renal vessels in rats treated with FK506 can 
develop focal medial necrosis, accumulation of eo-
sinophilic inclusions, and juxtaglomerular transfor-
mation, but not true arteritis (11,29). These nonin-
flammatory lesions may be the result not of a drug-
induced vasculitis but of arteriolar vasospasm 
similar to that reported with dopaminergic and ad-
renergic drugs (10). In human beings, focal necrosis 
of the pancreatic and peripancreatic arteries was 
first noted at autopsy in patients dying after organ 
transplantation (1). The concomitant presence of 
acute pancreatitis rendered an etiologic relationship 
with FK506 therapy unlikely. Subsequently, the 
Japanese FK506 study group demonstrated arterio-
lar fibrinoid necrosis and glomerular thrombi in hu-
man renal allograft biopsy samples obtained from 
patients maintained on FK506 (7,8). An improve-
FIG. 4. This afferent arteriole is completely occluded 
by a thrombus. The medial coat is permeated by a 
proteinaceous insudate and shows vacuolar change. 
A light peri arteriolar infiltrate of lymphocyte is 
present. but there was no significant interstitial in-
flammation and no tubulitis. The patient responded to 
a reduction in drug dosage. 
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FIG. 5. Globules of a pink eosinophilic material were 
seen in the media of this small arteriole. The size of 
these globules and lack of proximity of this vessel to a 
glomerulus make it unlikely that the myocytes ob-
served are a part of the juxtaglomerular apparatus. A 
similar lesion was reported in an experimental study 
on rats (11). 
ment in serum creatmme after reduction in drug 
dosage was shown in only one of the reported 
cases. No information on plasma FK506 levels was 
provided. 
The present study describes 10 patients with 
FK506-associated changes at the level of arterioles 
and glomerular capillaries, and correlates these 
changes with drug dosage, sequential plasma or 
whole blood FK506 levels, and serum creatinine 
levels. Such correlation is needed to provide firm 
evidence that FK506 can be toxic to 'the renal mi-
crovasculature. Plasma FK506 levels in cases 1-7 
and 10 were indeed elevated at the time of initial 
kidney biopsy. Reduction of FK506 dosage led to 
lower drug levels and serum creatinine levels in 
cases 1-6 and 10, providing a clear diagnosis of 
FK506 toxicity. Case 7 showed no decrease in cre-
atinine, but there was resolution of the glomerular 
thrombi on repeat biopsy. 
Cases 8 and 9 had plasma FK506 levels within the 
normal range at presentation. In case 8. reduction in 
Am J Surg Palhol. ~·olK 20. No. J. 1996 
drug dosage was followed by a decrease in serum 
creatinine from 4.0 to 1.7 mg/dl, strongly suggesting 
drug toxicity. In case 9, serial biopsies showed the 
glomerular thrombi to persist for several weeks, 
during which time the creatinine fluctuated between 
1.6 and 2.1 mg/dl. After maintaining a constant dose 
of FK506 for about 4 weeks, the drug intake was 
reduced from 10 to 8 mg/day. This was followed by 
resolution of the thrombi over the next 3-4 weeks. 
No definite improvement in the serum creatinine 
was observed. However, there was no clinical or 
histologic evidence of hypertension, acute rejec-
tion, or recurrent glomerulonephritis. The late on-
set of renal dysfunction (240 days after transplanta-
tion) excluded the possibility of ischemic/harvesting 
injury as being the cause of the glomerular capillary 
damage. Hence, this case also was felt to be an 
example of drug toxicity. The lack of elevated 
plasma FK506 levels is not inconsistent with this 
impression because correlation between drug levels 
FIG. 6. An interlobular artery with focal coagulative 
necrosis of the media and nuclear karyorrhexis. The 
interpretation of FK506 toxicity in this biopsy sample 
was supported by a concomitantly high FK506 level 
and improvement in renal allograft function when im-
munosuppression was reduced. This case has been 
previously reported, and this illustration is reproduced 
with permission from the publishers (19). 
.' 
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and clinical events in renal transplantation is not 
always perfect (2,8). 
Case 6 presented as acute hemolytic uremic syn-
drome (HUS) after cadaveric transplantation for 
systemic lupus erythematosus (SLE). Several alter-
nate explanations for the observed microvascular 
changes need to be considered. Spontaneously oc-
curring HUS and thrombotic thrombocytopenic 
purpura (TTP)-like syndromes are described in SLE 
(S). Glomerular thrombosis is reported in SO% of 
biopsies obtained from patients with proliferative 
lupus nephritis (9). However, the patient under dis-
cussion had no clinical evidence for active SLE at 
the time HUS was documented. Antinuclear anti-
bodies were undetectable, and serum complement 
levels were normal. A normal partial thromboplas-
tin time was evidence against the presence of cir-
culating lupus anticoagulants. Although we cannot 
definitely ascribe the clinical picture to FKS06, no 
other satisfactory explanation for HUS was docu-
mented. Discontinuation of FKS06 resulted in re-
covery over a period of several weeks. Another 
case of hemolytic uremic syndrome after FKS06 
therapy has been described in the literature (6), but 
rigorous proof that it was precipitated by the drug 
was again not provided. It is notable that HUS also 
has been reported to occur with CS (lS,22.27), and 
these patients apparently can be safely switched to 
FKS06 therapy without recurrence of HUS (13). 
The renal allograft biopsy samples evaluated in 
this study demonstrated a number of other morpho-
logic changes previously reported in the setting of 
FKS06 toxicity (4,8,19). These changes provide fur-
ther support for our belief that the microvascular 
pathology described in these patients is also drug 
mediated. Thus. isometric tubular cytoplasmic vac-
uolization was present in eight of 10 cases. and ar-
teriolar myocyte vacuolization was present in 10 of 
10 patients. Arteriolar hyalinosis was found at the 
time of initial biopsy in two patients (cases 3 and 4) 
and on follow-up biopsies in two additional patients 
(cases Sand 9). Blood pressure was within the nor-
mal range in these patients. although maintenance 
antihypertensive therapy was needed in 2 of 4 
cases. Donor disease was a potential contributing 
factor to the hyaline change in case 3, and diabetes 
was a complicating element in case S. However. in 
both instances a nodular configuration to the hya-
line deposits was observed similar to that previ-
ously reported in CS-associated arteriolopathy (IS). 
It is conceivable that the hyaline change observed 
in these vessels is drug induced and an aftermath of 
the acute microvascular injury documented earlier 
in the clinical course of these patients. 
The spectrum of histopathological changes ob-
served in these biopsy samples is similar to that 
reported with CS (IS). CS and FKS06 are structur-
ally unrelated compounds and bind to different cy-
tosolic proteins in target cells. Nonetheless. both 
drugs have a closely-related mechanism of action, 
resulting ultimately from a block in the transcription 
of interleukin-2 and other cytokine genes (28). 
Given these basic similarities in the immunosup-
pressive action of FK506 and CS, the overlap in 
their nephrotoxicity profile is not surprising. The 
actual mechanism of the microvascular injury de-
scribed in this study is unknown but may be related 
to FK506-induced vasospasm (12). Alternately, it 
may reflect direct endothelial injury and thrombosis 
secondary to alterations in the thromboxane A2-
prostaglandin PGI2 imbalance (18). 
In summary, the data presented indicate that 
FK506 can cause microvascular injury in human re-
nal allografts. The frequency of this occurrence is 
-1 % of renal transplant recipients if selection cri-
teria similar to those described in this study are 
used. By way of comparison. fibrin thrombi are re-
ported in 3% of diagnostic kidney biopsies obtained 
from CS-treated patients (15). Glomerular capillary 
and arteriolar thrombi fibrin also can be seen in 
biopsy samples showing ischemic injury, acute re-
jection with intimal arteritis, sepsis with dissemi-
nated intravascular coagulation, hemolytic uremic 
syndrome, recurrent lupus erythematosus, and ma-
lignant hypertension. Therefore, a diagnosis of 
FK506-induced microvascular toxicity should be 
made only after careful clinicopathologic correla-
tion and reasonable exclusion of other cases of 
s mall vessel injury. 0 
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